Genes (36)
Species: human : 33 mouse : 3 | |
Mouse | STAT5B | 6777 | signal transducer and activator of transcription 5B | Stat5 synergizes with T cell receptor/antigen stimulation in the development of lymphoblastic lymphoma. | Mouse | PBX1 | 5087 | pre-B-cell leukemia homeobox 1 | However, the subsequent demonstration that the only known DNA-binding module on the molecule, the Pbx1 homeodomain, is dispensable for the induction of lymphoblastic lymphoma in transgenic mice called into question the contribution made by the Pbx1 portion. | Mouse | MAP3K8 | 1326 | mitogen-activated protein kinase kinase kinase 8 | Tpl-2 transgenic mice expressing the wild-type protein from the proximal Lck promoter fail to show a biological phenotype, whereas mice expressing the truncated protein develop large-cell lymphoblastic lymphomas of T-cell origin. | Human | CD24 | 100133941 | CD24 molecule | N-glycans of the mouse glycoprotein HSA and its human analogue CD24 from lymphoblastoma, neuroblastoma and astrocytoma cell lines as well as from mouse brain homogenate were analysed and compared to each other | Human | TNFRSF13C | 115650 | tumor necrosis factor receptor superfamily, member 13C | BAFF-R expression was found only in B-cell lymphoma (44/80, positive cases/examined cases): B-lymphoblastic lymphoma 0/3, B-chronic lymphocytic leukemia/small lymphocytic lymphoma 4/4, mantle cell lymphoma 9/11, follicular lymphoma 10/14, diffuse large B-cell lymphoma (DLBCL) 11/25, marginal zone B-cell lymphoma 8/10, lymphoplasmacytic lymphoma 2/2, plasma cell myeloma 0/2, and Burkitt lymphoma 0/9, but not in T/NK cell lymphomas (0/19) or Hodgkin lymphoma (0/10). | Human | LEF1 | 51176 | lymphoid enhancer-binding factor 1 | Previously, precursor T lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LyL) was found to express TCF-1, and we find that 9 of 10 cases of T-ALL/LyL express LEF-1 as well as TCF-1, exhibiting uniform nuclear immunostaining for both transcription factors. | Human | MAGEC1 | 9947 | melanoma antigen family C, 1 | Only 1 of 8 Burkitt;s and 1 of 7 lymphoblastic lymphomas expressed a CT gene (CT7 and HOM-TES-14/SCP-1, respectively). | Human | DLEU2 | 8847 | deleted in lymphocytic leukemia 2 (non-protein coding) | An unusual example of a lymphoblastic lymphoma with evidence of both T-lymphocytic (Leu-1, Leu-2, Leu-3, OKT-6, terminal transferase-positive) and immature granulocytic (Mo1, chloroacetate esterase, lysozyme, alpha-1-antitrypsin-positive) cell proliferations was studied. | Human | TCL1A | 8115 | T-cell leukemia/lymphoma 1A | In B-cell neoplasia, TCL1 was expressed in the majority of the cases, including lymphoblastic lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma (60%), and primary cutaneous B cell lymphoma (55%). | Human | TNFRSF4 | 7293 | tumor necrosis factor receptor superfamily, member 4 | OX40/CD134 expression was characteristic of tumors composed of activated CD4(+) T cells and was not seen in small-cell T-cell lymphomas, lymphoblastic lymphomas, or other tumor types, including B-cell lymphomas or carcinomas. | Human | TCF7 | 6932 | transcription factor 7 (T-cell specific, HMG-box) | Previously, precursor T lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LyL) was found to express TCF-1, and we find that 9 of 10 cases of T-ALL/LyL express LEF-1 as well as TCF-1, exhibiting uniform nuclear immunostaining for both transcription factors. | Human | SYCP1 | 6847 | synaptonemal complex protein 1 | Only 1 of 8 Burkitt;s and 1 of 7 lymphoblastic lymphomas expressed a CT gene (CT7 and HOM-TES-14/SCP-1, respectively). | Human | STAT5A | 6776 | signal transducer and activator of transcription 5A | Stat5 synergizes with T cell receptor/antigen stimulation in the development of lymphoblastic lymphoma. | Human | SPN | 6693 | sialophorin | This case was initially interpreted as Ewing;s sarcoma (ES); however, additional studies revealed positivity for CD79a, CD43, and TdT expression, and an immunoglobulin heavy chain gene rearrangement (IgH-R) by polymerase chain reaction (PCR) established this to be a precursor B-lymphoblastic lymphoma. In contrast, lymphoblastic lymphomas (n = 4) were positive for CD3 and CD43 but negative for CD68, lysozyme, CD31, CD34, LN5, and myeloperoxidase. Expression of CD43 by B cells is often used as a diagnostic criterion in favor of a B-cell lymphoproliferative disorder, including small lymphocytic lymphoma/chronic lymphocytic leukemia, mantle cell lymphoma, Burkitt lymphoma, precursor B-lymphoblastic lymphoma, and a subset of marginal zone B-cell lymphomas. To develop a practical immunohistochemistry panel for distinguishing lymphoblastic lymphoma from Ewing sarcoma (ES), we evaluated 17 ES and 27 lymphoblastic lymphoma and leukemia cases with antibodies to CD99, terminal deoxynucleotidyl transferase (TdT), leukocyte common antigen (LCA), CD43, CD79a, CD20, CD3, vimentin, and neuron-specific enolase (NSE). | Human | PTPRJ | 5795 | protein tyrosine phosphatase, receptor type, J | Cases of precursor B-lymphoblastic lymphoma/leukemia did not express CD148 or CD27. | Human | PRKDC | 5591 | protein kinase, DNA-activated, catalytic polypeptide | Significantly, DNA-PKcs null mice demonstrate complete penetrance of thymic lymphoblastic lymphomas, strongly suggesting that Prkdc functions in mice as a T-cell tumour suppressor and, by virtue of its association with DNA repair and recombination, belongs to the ;caretaker; class of tumour-suppressor genes that includes ATM, BRCA1 and BRCA2 (ref. 15). | Human | NOTCH1 | 4851 | notch 1 | K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations | Human | MYC | 4609 | v-myc avian myelocytomatosis viral oncogene homolog | The c-myc translocation is likely crucial to the pathogenesis of the peripheral B-cell lymphoblastic lymphoma | Human | CD99 | 4267 | CD99 molecule | In addition, the possibility that MIC2 analysis may aid in the distinction of lymphoblastic lymphomas from small noncleaved lymphomas needs to be further addressed. To evaluate the usefulness of CD99 immunoreactivity in the diagnosis of leukemia cutis, we analyzed cases of cutaneous involvement by acute lymphoblastic leukemia/lymphoblastic lymphoma and acute myelogenous leukemia for the presence of this marker. To develop a practical immunohistochemistry panel for distinguishing lymphoblastic lymphoma from Ewing sarcoma (ES), we evaluated 17 ES and 27 lymphoblastic lymphoma and leukemia cases with antibodies to CD99, terminal deoxynucleotidyl transferase (TdT), leukocyte common antigen (LCA), CD43, CD79a, CD20, CD3, vimentin, and neuron-specific enolase (NSE). We conclude that CD99 is a sensitive but nonspecific marker for cutaneous involvement by acute lymphoblastic leukemia/lymphoblastic lymphoma and that CD99 is immunoreactive in the vast majority of cases (21 [88%] of 24 cases) of leukemia cutis. Caution should be taken when using MIC2 as a marker for Ewings sarcoma/ primitive neuroectodermal tumor or lymphoblastic lymphoma on paraffin sections of either soft tissue or bone marrow specimens. A limited panel of antibodies can lead to an erroneous diagnosis; B-lymphoblastic lymphoma may be negative for CD45 and CD20 but positive for CD99 and even for keratin, mimicking Ewings sarcoma. Without the use of antigen retrieval methods, lymphoblasts in cases of cutaneous involvement by acute lymphoblastic leukemia/lymphoblastic lymphoma were immunoreactive for CD99 in 9 of 9 cases. We conclude that among the SRCTs, MIC2 expression is not limited to Ewings sarcoma and primitive neuroectodermal tumors, but also shows strong and reliable expression in lymphoblastic lymphomas and related leukemias. We propose that 12E7 (CD99) expression, along with TdT, bcl-2, and CD34 reactivity in lymphoblastic lymphoma (LyL)/acute lymphoblastic leukemia (ALL), distinguishes this group of neoplasms from small noncleaved cell lymphomas (SNCLs) in both pediatric and adult patients, thereby narrowing the differential diagnosis of high-grade non-Hodgkins lymphomas and acute lymphoblastic leukemias in paraffin sections. When faced with the differential diagnosis of ES vs lymphoblastic lymphoma, an immunohistochemical panel that includes antibodies to CD99 and TdT is useful. | Human | MAX | 4149 | MYC associated factor X | Max protein expression is associated with survival of children with lymphoblastic lymphoma. | Human | LMO2 | 4005 | LIM domain only 2 (rhombotin-like 1) | Defects of the mismatch repair gene MSH2 are implicated in the development of murine and human lymphoblastic lymphomas and are associated with the aberrant expression of rhombotin-2 (Lmo-2) and Tal-1 (SCL). | Human | LMO1 | 4004 | LIM domain only 1 (rhombotin 1) | 60% of transgenic mice that overexpressed both OLIG2 and LMO1 developed pre-T lymphoblastic lymphoma/leukemia with large thymic tumor masses | Human | KRAS | 3845 | Kirsten rat sarcoma viral oncogene homolog | K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations | Human | TLX1 | 3195 | T-cell leukemia homeobox 1 | Since, in addition to our cases, involvement of the 9q34 breakpoint, together with 2q33, 14q11, or 7q34, has been reported in the literature in four lymphoblastic lymphoma patients, a gene located in 9q34 and referred to as tcl-3 may participate in the genesis of the T cell malignancies carrying these translocations. | Human | FLI1 | 2313 | Fli-1 proto-oncogene, ETS transcription factor | FLI-1 expression was seen in 29 of 41 (71%) ES/PNET, 7 of 8 (88%) lymphoblastic lymphomas, 0 of 8 poorly differentiated synovial sarcomas (PDSS), 0 of 32 rhabdomyosarcoma (RMS), 0 of 30 neuroblastomas, 0 of 8 esthesioneuroblastomas, 0 of 3 Wilms tumors, 0 of 1 mesenchymal chondrosarcoma, and in 1 of 1 desmoplastic round cell tumor. |
|